The Company reported revenue of $3.0 million in the Reported Period, compared to $2.7 million in the Comparable Period. During...
Quarter
Clinical Development Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of...
BEIJING, Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company...
FREMONT, Calif., August 08, 2024--(BUSINESS WIRE)--Amprius Technologies, Inc. ("Amprius"), (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon...
TheratechnologiesMONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company...
